Siltuximab for chimeric antigen receptor T-cell therapy–related CRS and ICANS: a multicenter retrospective analysis

Abstract: Chimeric antigen receptor T-cell (CAR-T) therapies are effective in many hematologic malignancies; however, adverse events including cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) can affect a significant number of patients. Those who dev...

Full description

Saved in:
Bibliographic Details
Main Authors: Amneet Bajwa, Qiuhong Zhao, Marcus Geer, Chenyu Lin, James Westholder, Joseph Maakaron, Monalisa Ghosh, David Frame, Ahmed Galal, Justin Tossey, Nausheen Ahmed, Evandro Bezerra, Nathan Denlinger, Marcos de Lima, Narendranath Epperla, Paolo Caimi, Timothy Voorhees
Format: Article
Language:English
Published: Elsevier 2025-01-01
Series:Blood Advances
Online Access:http://www.sciencedirect.com/science/article/pii/S2473952924006219
Tags: Add Tag
No Tags, Be the first to tag this record!